[Click eStock] "Deepnoid, Expected to More Than Double Performance This Year"

"Sales of Proprietary Generative AI Expected to Expand"

SK Securities analyzed that Deepnoid, which secured new growth engines through the development of generative artificial intelligence (AI), will see its sales this year grow by more than 100% compared to the previous year.

Deepnoid, established in 2008, is an AI-based medical imaging interpretation solution company that developed a generative AI model (Deep:GEN) using NVIDIA's H100. This AI model can be optimized by selectively applying the advantages of various open-source models, including the low-cost Chinese AI model DeepSeek, enabling accurate inference and generation at a relatively low cost. Deepnoid plans to dominate the domestic and international remote medical imaging interpretation service market through its medical imaging interpretation service called ‘M4CXR’ utilizing this technology.

Seonjae Heo, a researcher at SK Securities, stated, “Starting this year, with the launch of new generative AI solution products and the market penetration of existing learning-based AI solutions, Deepnoid’s medical AI sales proportion will begin to expand significantly,” adding, “The emergence of low-cost AI models like DeepSeek is expected to accelerate the popularization of AI, making this a noteworthy development.”

The performance outlook for this year is positive. SK Securities forecasted Deepnoid’s sales this year to increase by 102.8% from the previous year to 22 billion KRW, and operating losses are expected to narrow to -200 million KRW. Researcher Heo said, “Starting this year, the full-scale introduction of DeepNeuro, which secured non-reimbursable codes in Q4 last year, into domestic hospitals, DeepLung’s entry into health screening centers in the first half of this year, and the start of outsourced interpretation services in Q2 will drive sales growth in the medical AI sector,” adding, “The security and machine vision sectors are expected to continue securing orders from overseas and domestic OLED and secondary battery markets, serving as stable cash cows.”

Meanwhile, as of last year, Deepnoid’s sales composition by sector was 86.1% machine vision (semiconductors, displays, secondary batteries), 6.5% medical (hospitals and clinics), 5.6% security (airports and ports), and 1.8% others.